company background image

Energenesis BiomedicalLTD TPEX:6657 Stock Report

Last Price


Market Cap







17 May, 2022


Company Financials
6657 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

6657 Stock Overview

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan.

Energenesis BiomedicalLTD Competitors













Price History & Performance

Summary of all time highs, changes and price drops for Energenesis BiomedicalLTD
Historical stock prices
Current Share PriceNT$31.60
52 Week HighNT$60.50
52 Week LowNT$30.90
1 Month Change-25.47%
3 Month Change-25.82%
1 Year Change-40.49%
3 Year Change-24.94%
5 Year Changen/a
Change since IPO1.93%

Recent News & Updates

Apr 20
We Think Energenesis BiomedicalLTD (GTSM:6657) Can Easily Afford To Drive Business Growth

We Think Energenesis BiomedicalLTD (GTSM:6657) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

6657TW BiotechsTW Market

Return vs Industry: 6657 underperformed the TW Biotechs industry which returned 6.7% over the past year.

Return vs Market: 6657 underperformed the TW Market which returned 4.2% over the past year.

Price Volatility

Is 6657's price volatile compared to industry and market?
6657 volatility
6657 Average Weekly Movement5.3%
Biotechs Industry Average Movement5.3%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6657 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 6657's weekly volatility (5%) has been stable over the past year.

About the Company

201236Han-min Chen

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control.

Energenesis BiomedicalLTD Fundamentals Summary

How do Energenesis BiomedicalLTD's earnings and revenue compare to its market cap?
6657 fundamental statistics
Market CapNT$2.10b
Earnings (TTM)-NT$120.24m
Revenue (TTM)NT$7.49m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6657 income statement (TTM)
Cost of RevenueNT$2.13m
Gross ProfitNT$5.36m
Other ExpensesNT$125.60m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)-1.81
Gross Margin71.56%
Net Profit Margin-1,605.50%
Debt/Equity Ratio0%

How did 6657 perform over the long term?

See historical performance and comparison


Is Energenesis BiomedicalLTD undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6657's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6657's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: 6657 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 6657 is unprofitable, so we can't compare its PE Ratio to the TW market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6657's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 6657 is good value based on its PB Ratio (2.5x) compared to the TW Biotechs industry average (3.9x).

Future Growth

How is Energenesis BiomedicalLTD forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Energenesis BiomedicalLTD has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Energenesis BiomedicalLTD performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6657 is currently unprofitable.

Growing Profit Margin: 6657 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 6657 is unprofitable, and losses have increased over the past 5 years at a rate of 14.2% per year.

Accelerating Growth: Unable to compare 6657's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6657 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).

Return on Equity

High ROE: 6657 has a negative Return on Equity (-14.11%), as it is currently unprofitable.

Financial Health

How is Energenesis BiomedicalLTD's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6657's short term assets (NT$740.0M) exceed its short term liabilities (NT$27.2M).

Long Term Liabilities: 6657's short term assets (NT$740.0M) exceed its long term liabilities (NT$6.2M).

Debt to Equity History and Analysis

Debt Level: 6657 is debt free.

Reducing Debt: 6657 has no debt compared to 5 years ago when its debt to equity ratio was 15.3%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6657 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6657 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 13.3% each year


What is Energenesis BiomedicalLTD current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6657's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6657's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6657's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6657's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6657 has not reported any payouts.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Han-min Chen

no data


Dr. Han-min Chen is Co-Founder, Vice Chairman and General Manager at Energenesis Biomedical CO.,LTD. He has many years in the research of biomedicine, specializing in biochemistry and enzyme chemistry. He...


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.7%.

Top Shareholders

Company Information

Energenesis Biomedical CO.,LTD.'s employee growth, exchange listings and data sources

Key Information

  • Name: Energenesis Biomedical CO.,LTD.
  • Ticker: 6657
  • Exchange: TPEX
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$2.103b
  • Shares outstanding: 66.54m
  • Website:

Number of Employees


  • Energenesis Biomedical CO.,LTD.
  • No.21, Ln.583, Ruiguang Road
  • 6F.-3, Neihu Dirstrict
  • Taipei City
  • 11492
  • Taiwan


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/17 00:00
End of Day Share Price2022/05/16 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.